BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene solid tumor pipeline and clinical trials.
BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the furtherest reaches of the globe. Learn more about the BeiGene story.
A global biotechnology innovator focused on improving treatment outcomes and patient access